

Sustainable Finance Disclosure Regulation Policy

Cross-Border Impact Ventures (“**CBIV**”) is the investment advisor for the Women’s and Children’s Health Technology EU Fund SCSp (“**WCHT-EU Fund**” or the “**Fund**”), a Fund of Funds that invests predominately in the Women's and Children's Health Technology Master Fund I, L.P. and Women's and Children's Health Technology Master Fund II, L.P., (together, the “Master Funds”) for which CBIV is also an investment advisor.

The Women’s and Children’s Health Technology EU Fund is categorized as an Article 9 financial product within the meaning of SFDR and has socially Sustainable Investments as its objective.

SFDR Compliance Framework & Policy

1.1.Objective, article and allocation

The Women’s and Children’s Health Technology EU Fund’s sustainable investment objective is to contribute to addressing the unmet health needs of women, children and adolescents caused by decades of underinvestment in the sector and other market failures that result in health outcome inequalities related to gender, race, wealth and country of residence. The Women’s and Children’s Health Technology EU Fund aims at investing in other funds, the underlying assets of which comprise commercial stage health technology companies addressing such needs. The Women’s and Children’s Health Technology EU Fund is categorized as an Article 9 financial product within the meaning of SFDR and has socially Sustainable Investments as its objective.

The General Partner expects that 80% all of the assets of the Fund will qualify as Sustainable Investments, with the exception of the use of derivatives for hedging purposes, cash and other liquid investments.

1.2. Key Impact Indicators

The Fund will measure the attainment of the Sustainable Investment Objective through Sustainability Indicators (“Key Impact Indicators”) such as:

- The number of women’s, children’s and/or adolescents’ lives improved
- The number or women’s, children’s and/or adolescents’ lives saved
- The number or women’s, children’s and/or adolescents’ beneficiaries accessed

1.3 Do No Significant Harm Principle

The General Partner seeks to ensure that its Portfolio Investments do not significantly harm any sustainable investment objective, by: screening potential investments and monitoring existing investments against

- i) The principal adverse impact indicators set out in the Regulatory Technical Standard of the SFDR
- ii) Minimum environmental and social safeguards, such as those referred in the Taxonomy Regulation when applicable
- iii) Refraining from investing in companies identified in the IFC Exclusion List

1.4 Index

The Fund does not identify an index as reference benchmark. The fund will track the attainment of its Sustainable Investment Objective by monitoring portfolio companies and will transition to a relevant index for benchmarking purposes when appropriate standards will be available.

2. Principal Adverse Impact Indicators (PASIs)

2.1 Identification and prioritization of PASIs, due diligence policies and mitigants

The Women's and Children's Health Technology EU Fund relies on its General Partner to ensure that its Portfolio Investments do not significantly harm any sustainable investment objective, by screening potential investments and monitoring existing investments against the principal adverse impact indicators set out in the Regulatory Technical Standard of the SFDR

The General Partner will not knowingly invest in any Portfolio Investment which is expected, or is determined, to do significant harm to the sustainable investment objective and will ensure proper exchange of information with the Investment Advisor to ensure that the assets underlying the Master Funds and the other investments qualify as sustainable.

The General Partner intends to fully consider PASI by the first investment. All due disclosures related to PASI will be disclosed by the General Partner by the time of the first investment of the fund.

2.2 Engagement Policies

The Fund engages its portfolio companies to stimulate the application of global best practices in their operations. Engagement actions include, for instance:

- Engagement with portfolio companies to ensure that they understand and, as far as commercially practical, adhere to the IFC Performance Standards or a similar set of social and environmental standards.
- Assisting companies in developing a corrective ESG action plan where necessary

3. Integration of Sustainability Risks into the Fund's investment decision-making process

The Women's and Children's Health Technology EU Fund relies on its general partner, acting as a sub-threshold alternative investment fund manager of the Fund to ensure that ESG considerations are duly considered in all stages of its investment process. This means that the General Partner assesses the sustainability risks which could have an actual or potential material negative impact on the value of Fund investments before and after investment decisions have been made. In addition, The General Partner assesses the potential negative impacts of investment decisions and the impacts of underlying assets and investee companies on environmental, social and employee matters, respect for human rights, anti-corruption and anti-bribery matters.

As an investor predominately in Women's and Children's Health Technology Master Fund I, L.P. and Women's and Children's Health Technology Master Fund II, L.P., (together, the “**Master Funds**”), the General Partner will rely on the information received from the Investment Advisor at Master Funds level to conduct its pre-investment due diligence before making an investment decision. The assessment of sustainability risks and potential negative externalities is an important component of the General Partner's due diligence process for any potential investment.

The Fund’s Investment Advisor will monitor investments to ensure that corrective action plans are implemented where necessary, that ESG risks are identified and addressed, and that environmental and social opportunities are considered.

The Fund will request its investees to report annually on their environmental and social performance as well as on the beneficiaries they reach in each target markets according to a pre-determined process established at the time of investment. The Fund’s annual Report will aggregate the ESG information and impact information received from its investees.